- Home
- SOL vs XFOR Comparison
SOL vs XFOR Comparison
Compare SOL & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOL
- XFOR
- Stock Information
- Founded
- SOL 2005
- XFOR 2014
- Country
- SOL United States
- XFOR United States
- Employees
- SOL N/A
- XFOR N/A
- Industry
- SOL Semiconductors
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOL Technology
- XFOR Health Care
- Exchange
- SOL Nasdaq
- XFOR Nasdaq
- Market Cap
- SOL 98.5M
- XFOR 84.3M
- IPO Year
- SOL 2008
- XFOR N/A
- Fundamental
- Price
- SOL $1.87
- XFOR $3.42
- Analyst Decision
- SOL Strong Buy
- XFOR Strong Buy
- Analyst Count
- SOL 2
- XFOR 3
- Target Price
- SOL $4.50
- XFOR $34.17
- AVG Volume (30 Days)
- SOL 176.4K
- XFOR 412.4K
- Earning Date
- SOL 11-13-2025
- XFOR 11-12-2025
- Dividend Yield
- SOL N/A
- XFOR N/A
- EPS Growth
- SOL N/A
- XFOR N/A
- EPS
- SOL N/A
- XFOR N/A
- Revenue
- SOL $68,445,000.00
- XFOR $32,774,000.00
- Revenue This Year
- SOL N/A
- XFOR $1,307.51
- Revenue Next Year
- SOL $45.37
- XFOR N/A
- P/E Ratio
- SOL N/A
- XFOR N/A
- Revenue Growth
- SOL N/A
- XFOR 5721.31
- 52 Week Low
- SOL $1.04
- XFOR $1.35
- 52 Week High
- SOL $3.00
- XFOR $26.83
- Technical
- Relative Strength Index (RSI)
- SOL 50.30
- XFOR 51.89
- Support Level
- SOL $1.85
- XFOR $3.31
- Resistance Level
- SOL $1.92
- XFOR $3.63
- Average True Range (ATR)
- SOL 0.02
- XFOR 0.28
- MACD
- SOL -0.00
- XFOR -0.03
- Stochastic Oscillator
- SOL 41.92
- XFOR 56.34
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has globalised Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. Majority of revenue is From Electricity Generation. The company operates in China, USA, Germany, UK, Spain, France, Poland, Italy, Hungary, Luxembourg. Majority of revenue is from Italy.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.